MTOR and neoplasm: Sharma et al. further demonstrated proficiency in combining therapy of PI3K/mTOR inhibitor (NVP-LDE-225) and sHH inhibitor (NVP-BEZ-235) on PaCSCs characteristics, microRNA regulation network, and tumor growth by controlling the expression of pluripotency conserving factors Nanog, Oct-4, Sox-2, and cMyc along with repression of Gli transcription.